Lipocine (NASDAQ:LPCN) Coverage Initiated at StockNews.com

StockNews.com started coverage on shares of Lipocine (NASDAQ:LPCN) in a research note issued to investors on Wednesday. The firm issued a hold rating on the specialty pharmaceutical company’s stock.

Separately, Alliance Global Partners initiated coverage on shares of Lipocine in a research report on Tuesday, September 24th. They set a “buy” rating and a $10.00 price target on the stock.

Lipocine Trading Up 6.6 %

Shares of NASDAQ:LPCN opened at $4.88 on Wednesday. Lipocine has a 1-year low of $2.76 and a 1-year high of $11.79. The stock has a market cap of $26.10 million, a PE ratio of -6.42 and a beta of 1.24. The stock’s fifty day simple moving average is $5.08 and its two-hundred day simple moving average is $5.28.

Lipocine (NASDAQ:LPCN) last posted its quarterly earnings data on Thursday, November 7th. The specialty pharmaceutical company reported ($0.44) earnings per share for the quarter. On average, sell-side analysts forecast that Lipocine will post -0.78 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Lipocine

A hedge fund recently raised its stake in Lipocine stock. Renaissance Technologies LLC increased its stake in Lipocine Inc. (NASDAQ:LPCN) by 21.8% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 25,697 shares of the specialty pharmaceutical company’s stock after buying an additional 4,600 shares during the period. Renaissance Technologies LLC owned 0.48% of Lipocine worth $212,000 at the end of the most recent reporting period. 9.11% of the stock is owned by institutional investors and hedge funds.

About Lipocine

Lipocine Inc, a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate.